Modulation of p-glycoprotein function by caveolin-1 phosphorylation. J Neurochem

Laboratoire de médecine moléculaire, Hôpital Sainte-Justine, Université du Québec à Montréal, Montréal, Québec, Canada.
Journal of Neurochemistry (Impact Factor: 4.28). 05/2007; 101(1):1-8. DOI: 10.1111/j.1471-4159.2006.04410.x
Source: PubMed


p-glycoprotein (p-gp) is an ATP-binding cassette transporter and its overexpression is responsible for the acquisition of the multidrug resistance phenotype in human tumors. p-gp is localized at the blood-brain barrier and is involved in brain cytoprotection. Our previous work used immunoprecipitation to show that caveolin-1 can interact with p-gp. In this study, we provide evidence that caveolin-1 regulates p-gp transport activity in a rat brain endothelial cell line (RBE4). Down-regulation of caveolin-1 by siRNA reduced the interaction between p-gp and caveolin-1, followed by a decrease in [3H]-Taxol and [3H]-Vinblastine accumulation in RBE4 cells. The latter result showed that down-regulation of caveolin-1 enhanced p-gp transport activity. RBE4 cells were also transfected with Sarcoma in order to modulate caveolin-1 phosphorylation. Overexpression of Sarcoma, a protein tyrosine kinase, stimulated caveolin-1 phosphorylation and increased both [3H]-Taxol and [3H]-Vinblastine accumulation as well as Hoechst 33342 accumulation. Transfection of caveolin-1 inhibits p-gp transport activity. Conversely, transfection of the mutant cavY14F decreased the p-gp/caveolin-1 interaction and reduced accumulation of the two p-gp substrates. Thus, our data show that caveolin-1 regulates p-gp function through the phosphorylation state of caveolin-1 in endothelial cells from the blood-brain barrier.

Full-text preview

Available from:
  • Source
    • "Phosphorylation of caveolin-1 at tyrosine-14 in vitro in rat brain endothelial cells promotes its physical interaction with P-glycoprotein. This negatively regulates P-glycoprotein transport activity (Barakat et al. 2007, 2008). Therefore, in this study, double immunolabeling was performed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: J. Neurochem. (2012) 122, 962–975. P-glycoprotein (ABCB1/MDR1, EC, the major efflux transporter at the blood–brain barrier (BBB), is a formidable obstacle to CNS pharmacotherapy. Understanding the mechanism(s) for increased P-glycoprotein activity at the BBB during peripheral inflammatory pain is critical in the development of novel strategies to overcome the significant decreases in CNS analgesic drug delivery. In this study, we employed the λ-carrageenan pain model (using female Sprague–Dawley rats), combined with confocal microscopy and subcellular fractionation of cerebral microvessels, to determine if increased P-glycoprotein function, following the onset of peripheral inflammatory pain, is associated with a change in P-glycoprotein trafficking which leads to pain-induced effects on analgesic drug delivery. Injection of λ-carrageenan into the rat hind paw induced a localized, inflammatory pain (hyperalgesia) and simultaneously, at the BBB, a rapid change in colocalization of P-glycoprotein with caveolin-1, a key scaffolding/trafficking protein. Subcellular fractionation of isolated cerebral microvessels revealed that the bulk of P-glycoprotein constitutively traffics to membrane domains containing high molecular weight, disulfide-bonded P-glycoprotein-containing structures that cofractionate with membrane domains enriched with monomeric and high molecular weight, disulfide-bonded, caveolin-1-containing structures. Peripheral inflammatory pain promoted a dynamic redistribution between membrane domains of P-glycoprotein and caveolin-1. Disassembly of high molecular weight P-glycoprotein-containing structures within microvascular endothelial luminal membrane domains was accompanied by an increase in ATPase activity, suggesting a potential for functionally active P-glycoprotein. These results are the first observation that peripheral inflammatory pain leads to specific structural changes in P-glycoprotein responsible for controlling analgesic drug delivery to the CNS.
    Journal of Neurochemistry 06/2012; 122(5):962-75. DOI:10.1111/j.1471-4159.2012.07831.x · 4.28 Impact Factor
  • Source
    • "Secondly P-gp actively mediates cholesterol redistribution in the plasma membrane (Garrigues et al., 2002). Thirdly, phosphorylated caveolin-1 associates with P-gp in caveolae and inhibits its activity (Barakat et al., 2007). Fourthly, P-gp expression is coupled with ATP release from cells (Roman et al., 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lipid nanocapsules (LNCs) have been shown to improve paclitaxel (Ptx) bioavailability and transport across an intestinal barrier model. In the present study, the interaction between P-glycoprotein (P-gp) and LNC transport across Caco-2 cells are investigated. Transport experiments have been performed on Caco-2 cells displaying different P-gp activities (early and later cell passages). The permeability of Ptx encapsulated in LNCs has been studied in the presence of P-gp inhibitors (verapamil and vinblastin) or unloaded LNCs. The uptake of dye-labelled LNCs was also observed in the presence of the same inhibitors. It was found that the permeability of Ptx varied depending on the passages with later ones showing higher absolute values (5.74+/-1.21 cms(-1) vs 133.41+/-5.74 cms(-1)). P-gp inhibition obtained with verapamil or vinblastin improved Ptx transport up to 98%. LNCs have also demonstrated their capacity to increase their own transport. Experiments performed with dye-labelled LNCs demonstrated an enhancement of the uptake of dye (Nile red), only in the presence of verapamil. These results demonstrated an effect of P-gp on the transport of Ptx when loaded in LNCs and support a direct effect of P-gp on their endocytosis in Caco-2 cells. These finding may assist in the development of new nanomedicine for oral administration.
    European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 05/2010; 40(5):422-9. DOI:10.1016/j.ejps.2010.04.015 · 3.35 Impact Factor
  • Source
    • "Recent experiments with a rat brain endothelial cell line showed increased interaction of caveolin-1 with P-glycoprotein is associated with decreased transporter activity, and that Tyr-14 phosphorylation of caveolin-1 by transfected Src kinase promotes this interaction (Barakat et al., 2007). We show here that exposing intact brain capillaries to either VEGF or the Src kinase activating peptide YEEIP increased specific Tyr-14 phosphorylation of caveolin-1; VEGF-induced caveolin phosphorylation was blocked by the Src kinase inhibitor, PP2. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased brain expression of vascular endothelial growth factor (VEGF) is associated with neurological disease, brain injury, and blood-brain barrier (BBB) dysfunction. However, the specific effect of VEGF on the efflux transporter P-glycoprotein, a critical component of the BBB, is not known. Using isolated rat brain capillaries and in situ rat brain perfusion, we determined the effect of VEGF exposure on P-glycoprotein activity in vitro and in vivo. In isolated capillaries, VEGF acutely and reversibly decreased P-glycoprotein transport activity without decreasing transporter protein expression or opening tight junctions. This effect was blocked by inhibitors of the VEGF receptor flk-1 and Src kinase, but not by inhibitors of phosphatidylinositol-3-kinase or protein kinase C. VEGF also increased Tyr-14 phosphorylation of caveolin-1, and this was blocked by the Src inhibitor PP2. Pharmacological activation of Src kinase activity mimicked the effects of VEGF on P-glycoprotein activity and Tyr-14 phosphorylation of caveolin-1. In vivo, intracerebroventricular injection of VEGF increased brain distribution of P-glycoprotein substrates morphine and verapamil, but not the tight junction marker, sucrose; this effect was blocked by PP2. These findings indicate that VEGF decreases P-glycoprotein activity via activation of flk-1 and Src, and suggest Src-mediated phosphorylation of caveolin-1 may play a role in downregulation of P-glycoprotein activity. These findings also imply that P-glycoprotein activity is acutely diminished in pathological conditions associated with increased brain VEGF expression and that BBB VEGF/Src signaling could be targeted to acutely modulate P-glycoprotein activity and thus improve brain drug delivery.
    The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 01/2010; 30(4):1417-25. DOI:10.1523/JNEUROSCI.5103-09.2010 · 6.34 Impact Factor
Show more